These enrolling esearch studies are for patients with newly diagnosed AML.
We differentiate the clinical trials according to the patient group they aim to include, from fit, unfit and residual AML.
FIT AML
HOVON 501
Intensive chemotherapy in combination with venetoclax/placebo.
Unknown starting time
Sites: Oslo universitetssykehus, Haukeland universitetssjukehus, Stavanger universitetssjukehus, Universitetssjukehuset i Nord Norge, Sankt Olavs Hospital
Quantum-wild
For FLT3-ITD negative patients in combination with intensive chemotherapy and as maintenance.
Starting Winter 2024/2025
Sites: UNN, OUS
Un FIT AML
Repurposing in personalized leukemia therapy
Hydroxyurea + Valproat vs. 6-mercaptopurine + Valproat: newly diagnosted AML patients, not candidates for standard intensive treatment R/R AML, high risk MDS
Start time: ongoing
Sites: Haukeland universitetssjukehus, Bjørn Tore Gjertsen
QC+VPA
Quinacrine;Mepacrine + Valproic acid; Orfiril Long depot caps.) off- label treatment outside a clinical study.
R/R AML patients with chronic infections unfit for other available treatment.
Start time: ongoing
Sites: Haukeland universitetssjukehus, Bjørn Tore Gjertsen
Residual disease AML
IMPRESS
- IMPRESS: early KMML/AML, MDS and AML high risk genetics
- IMPRESS AML MELFALAN: including AML/MDS with low to normal ( up to 50%) cellularity, excluding patients with more than two cytogenetic aberrations or chromosome 7 aberrations, TP52 >20%.
- IMPRESS AML ACTINOMYCIN D Including NPM1 mutated AML/high risk MDS, exluding FLT3 mutation
sites: Haukeland universitetssjukehus, Bjørn Tore Gjertsen, XX Emil Nyquist.
NB